Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)
| Autor: | A, Josting, C, Rudolph, M, Mapara, J-P, Glossmann, M, Sieniawski, M, Sienawski, M, Sieber, H H, Kirchner, B, Dörken, D K, Hossfeld, J, Kisro, B, Metzner, W E, Berdel, V, Diehl, A, Engert |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Vincristine Adolescent Injections Subcutaneous medicine.medical_treatment Gastroenterology Dexamethasone Disease-Free Survival Recurrence DHAP Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Refractory Hodgkin Lymphoma Humans Autologous transplantation Infusions Intravenous Antineoplastic Agents Alkylating Cyclophosphamide Melphalan Etoposide Peripheral Blood Stem Cell Transplantation Chemotherapy Dose-Response Relationship Drug business.industry Cytarabine Hematology Middle Aged Hodgkin's lymphoma medicine.disease Carmustine Combined Modality Therapy Hodgkin Disease Chemotherapy regimen Surgery Regimen Methotrexate Treatment Outcome Oncology Female Cisplatin business medicine.drug |
| Zdroj: | Annals of Oncology. 16:116-123 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdi003 |
| Popis: | Background: We designed a dose- and time-intensified high-dose sequential chemotherapy regimen for patients with relapsed and refractory Hodgkin lymphoma (HD). Patients and methods: Eligibility criteria included age 18 – 65 years, histologically proven primary progressive (PD) or relapsed HD. Treatment consisted of two cycles DHAP (dexamethasone, highdose cytarabine, cisplatinum); patients with chemosensitive disease received cyclophosphamide followed by peripheral blood stem cell harvest; methotrexate plus vincristine, etoposide and BEAM plus peripheral blood stem cell transplantation (PBSCT). Results: A total of 102 patients (median age 34 years, range 18– 64) were enrolled. The response rate was 80% (72% complete response, 8% partial response). With a median follow-up of 30 months (range 3 – 61 months), freedom from second failure (FF2F) and overall survival (OS) were 59% and 78% for all patients, respectively. FF2F and OS for patients with early relapse were 62% and 81%, for late relapse 65% and 81%; for PD 41% and 48%, and for multiple relapse 39% and 48%, respectively. In multivariate analysis response after DHAP (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|